Wyoming
Department
of Health

Division of Healthcare Financing

Medicaid Pharmacy News

Dear Providers: December 30, 2011

2012 PREFERRED DRUG LIST/ADDITIONAL THERAPEUTIC CRITERIA CHART/ DOSAGE LIMITATION CHART

Included in this newsletter is a copy of the Wyoming Medicaid 2012 Preferred Drug List (PDL), Additional Therapeutic Criteria Chart, and the Dosage Limitation Chart. This information is also available at www.wyequalitycare.org.

PRIOR AUTHORIZATION CHANGES

Prior authorizations currently on file for the following medications: Aricept, Lipitor, Concerta, Zyprexa, Xyzal Solution, and Kadian 20mg, 30mg, 50mg, 60mg, 80mg, and 100mg; **will be changed to allow only the generic formulations** by February 1, 2012. If the brand name medication is medically necessary, the prescriber may complete a ***Brand Name Prior Authorization form*** and send to Goold Health Systems for review. If approved, a one year prior authorization will be put in place for the brand name formulation. In addition, any prior authorizations for generic levalbuterol concentrated nebulizer solution will be changed to the brand name Xopenex concentrated nebulizer solution.

VENLAFAXINE EXTENDED RELEASE CAPSULES AND TABLETS

Effective January 1, 2012 **venlafaxine extended release (ER) CAPSULES will be PREFERRED**, while **the venlafaxine ER tablets will become non-preferred**. Clients who are taking the ER tablets will be asked to switch over to the capsule formulation and any clients who have a prior authorization in place for the venlafaxine ER tablets will also be switched to capsules.

WYOMING MEDICAID
Preferred Drug List (PDL) - JANUARY 1, 2012

Drug classes not included on this list are not managed through a Preferred Drug List (PDL).
HOWEVER, THIS EXCLUSION IS NOT A GUARANTEE OF PAYMENT OR COVERAGE. Dosage limits and other requirements may apply.

Drugs new to market are non-preferred until a clinical review has been completed. PA criteria will apply to both the pediatric population, as well as the adult population for those plans where PA/PDL limits are allowed.

Unless otherwise noted on the PDL, generic substitution is mandatory.

Yellow highlighted items below indicate new changes to the PDL. Red font indicates quantity/dosage limits apply. *Indicates BRAND is Preferred. May Use DAW 5.
Contact the GHS PA Helpdesk @ 877-207-1126 for prior authorization if client has primary insurance that will not cover the brand name medication.

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at *http://wyequalitycare.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES (THIS LIST IS NOT ALL INCLUSIVE. PLEASE CONTACT GHS FOR QUESTIONS)
ALLERGY / ASTHMA	**ANTIHISTAMINES, MINIMALLY SEDATING** cetirizine fexofenadine loratadine		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	CLARINEX levocetirizine
	ANTIHISTAMINE/DECONGESTANT COMBINATIONS cetirizine/pseudoephedrine fexofenadine/pseudoephedrine loratadine/pseudoephedrine		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	CLARINEX-D
	ANTICHOLINERGIC BRONCHODILATORS ipratropium SPIRIVA		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for Spiriva 5 day STARTER package will be allowed one (1) time per recipient.	ATROVENT HFA
	CORTICOSTEROID / BRONCHODILATOR COMBO'S ADVAIR/HFA DULERA SYMBICORT		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for Advair 7 and 14-day STARTER package will be allowed one (1) time per recipient.	
	LEUKOTRIENE MODIFIERS SINGULAIR TABS,CHEWABLES, GRANULES		Trial and failure of preferred agent greater than or equal to 30 days in the last 12 months will be	zafirlukast ZYFLO
	NASAL ANTIHISTAMINES azelastine		Trial and failure of preferred agent greater than or equal to 90 days in the last 12 months will be required before approval can be given for a non-preferred agent.	ASTEPRO 0.15% PATANASE
	NASAL STEROIDS fluticasone **NASACORT AQ*** NASONEX		Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Rhinocort will be approved for pregnancy.	BECONASE AQ flunisolide OMNARIS RHINOCORT triamcinolone (BRAND IS PREFERRED) VERAMYST
	SHORT ACTING BRONCHODILATORS - INHALERS PROAIR HFA PROVENTIL HFA VENTOLIN HFA XOPENEX HFA		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	ALUPENT
	SHORT ACTING BRONCHODILATORS - NEBULIZERS albuterol neb **XOPENEX neb***		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	ACCUNEB levalbuterol (BRAND IS PREFERRED) METAPROTERENOL
	STEROID INHALANTS ASMANEX budesonide FLOVENT HFA/DISK QVAR		Trial and failure of three (3) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Alvesco will be approved for a history of oral thrush with steroid inhalants.	AEROBID/AEROBID-M ALVESCO ASMANEX STARTER PACK (use preferred) AZMACORT PULMICORT
ALZHEIMERS	**ALZHEIMER AGENTS**	donepezil EXELON PATCH/SOLUTION galantamine/ER NAMENDA rivastigmine capsules	Client must have a diagnosis of dementia.	ARICEPT 23MG (use preferred) donepezil ODT (use preferred)
ANALGESICS	**BUPRENORPHINE COMBINATIONS**	SUBOXONE/FILM	Client must have a diagnosis of opioid dependence or abuse. This is not to be used to for the treatment of chronic pain. Only one (1) narcotic prescription will be allowed between fills. Subutex will be approved for clients pregnant or nursing or with a documented allergy to naloxone. Dosage limits apply (Max Dose: 24mg/day).	SUBUTEX

WYOMING MEDICAID
Preferred Drug List (PDL) - JANUARY 1, 2012

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at *http://wyequalitycare.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES (THIS LIST IS NOT ALL INCLUSIVE. PLEASE CONTACT GHS FOR QUESTIONS)
ANALGESICS *Continued*	**LONG-ACTING**		Trial and failure of a preferred agent(s) greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Fentanyl patches are limited to one patch every 72 hours. C-IIIs and C-IVs are not included and are available without prior authorization with the exception of Butrans (generic substitution is mandatory). **Butrans requires a trial of morphine sulfate or low dose trial of fentanyl patch. ***Embeda requires trial of preferred and client must have diagnosis of drug/ substance abuse.	AVINZA BUTRANS** EMBEDA*** KADIAN (10mg/200mg) morphines sulfate ER capsules NUCYNTA ER OPANA ER (5mg/10mg/20mg/30mg/40mg) oxymorphone ER (7.5mg/15mg) OXYCONTIN/CR
	fentanyl patch morphine sulfate ER tablets			
	SHORT-ACTING C-IIs		Trial and failure of three (3) preferred agents greater than or equal to a 6 day supply in the last 90 days will be required before approval can be given for a non-preferred agent.	EXALGO levorphanol NUCYNTA oxymorphone oxycodone/IBU
	codeine sulfate hydromorphone morphine sulfate oxycodone oxycodone/APAP oxycodone/ASA			
	TRAMADOL PRODUCTS		Trial and failure of a preferred agent(s) greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Quantity and dosage limits apply (max 8 tabs/day).	CONZIP RYBIX ODT tramadol/apap tramadol ER
	tramadol			
ANDROGENS	**TESTOSTERONE TOPICAL GELS**		Testosterone agents are only allowed for diagnosis of hypogonadism or insufficient testosterone production. Prior authorization required for non-preferred agent.	TESTIM GEL
		ANDROGEL		
ANTIBIOTICS	**QUINOLONES**			AVELOX FACTIVE NOROXIN PROQUIN
	ciprofloxacin/ER levofloxacin ofloxacin			
	DOXYCYCLINE			ADOXA (use preferred) DORYX (use preferred) ORACEA (use preferred)
	doxycycline			
	MINOCYCLINE			SOLODYN (use preferred)
	minocycline/ER			
ANTICOAGULANTS	**LOW MOLECULAR WEIGHT HEPARIN (LMWH)**			enoxaparin (BRAND IS PREFERRED) FRAGMIN (use preferred) ***LOVENOX 300MG/3ML (USE PREFERRED)***
	LOVENOX*			
	DIRECT THROMBIN INHIBITOR		Client must have diagnosis of non-valvular atrial fibrillation and relative contraindication to warfarin for approval.	
		PRADAXA		
	SELECTIVE FACTOR XA INHIBITOR		Client must have diagnosis of non-valvular atrial fibrillation or prophylaxis of deep vein thrombosis which can lead to pulmonary embolism in clients undergoing hip or knee replacement.	
		XARELTO		
ANTICONVULSANTS	**DIAZEPAM RECTAL GEL**			diazepam gel (BRAND IS PREFERRED)
	DIASTAT*			

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at *http://wyequalitycare.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES (THIS LIST IS NOT ALL INCLUSIVE. PLEASE CONTACT GHS FOR QUESTIONS)
ANTIDEPRESSANTS	**ANTIDEPRESSANTS**		Trial and failure of two (2) preferred agents greater than or equal to six (6) weeks will be required before approval can be given for a non-preferred agent. Trazodone, buspirone, fluvoxamine, MAO inhibitors, TCA's, bupropion IR and venlafaxine IR do not require prior authorization but **will not count** towards meeting preferred therapy requirements. *Cymbalta will be approved for a diagnosis of peripheral neuropathy and osteoarthritis of the knee. **Lexapro will be approved for adolescents between the ages of 12 - 17.	***fluoxetine tablets** (use preferred)* ***mirtazapine 7.5mg and mirtazapine rapid-dissolve tablets** (use preferred)* ***venlafaxine ER tablets** (use preferred)* APLENZIN CYMBALTA* LEXAPRO** PRISTIQ VIIBRYD
	bupropion ER/SR/XL citalopram fluoxetine capsules mirtazapine 15, 30, and 45mg paroxetine IR/CR sertraline venlafaxine ER capsules			
ANTIHYPERTENSIVES	**ACE INHIBITORS**		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	benazepril captopril enalapril fosinopril lisinopril moexipril perindopril quinapril ramipril trandolapril			
	ACE INHIBITORS AND DIURETICS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	benazepril/HCTZ captopril/HCTZ enalapril/HCTZ fosinopril/HCTZ lisinopril/HCTZ moexipril/HCTZ quinapril/HCTZ			
	ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)		Trial and failure of an ACE Inhibitor greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for preferred ARB. Non-preferred ARBs and ARB/diuretic combinations also require a history of ALL preferred ARBs before approval can be given.	ATACAND EDARBI eprosartan 600mg TEVETEN 400mg
		AVAPRO BENICAR DIOVAN losartan MICARDIS		
	ARBs AND DIURETICS			ATACAND HCT TEVETEN HCT
		AVALIDE BENICAR HCT DIOVAN HCT losartan HCT MICARDIS HCT		
	ARB COMBINATIONS			AZOR
		EXFORGE/EXFORGE-HCT		TWYNSTA (use separate agents) TRIBENZOR (use separate agents)
	ALPHA-BLOCKERS			clonidine patch (BRAND IS PREFERRED) NEXICLON XR (use preferred)
	CATAPRES PATCHES* clonidine			

WYOMING MEDICAID
Preferred Drug List (PDL) - JANUARY 1, 2012

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at *http://wyequalitycare.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES (THIS LIST IS NOT ALL INCLUSIVE. PLEASE CONTACT GHS FOR QUESTIONS)
ANTIPSYCHOTICS	**ATYPICAL ANTIPSYCHOTICS**		**Seroquel doses less than 100mg will require prior authorization without a diagnosis of mood disorder or major depressive disorder. For titration doses, contact the GHS Pharmacy Help Desk for an override. Non-preferred agents (Fanapt, Latuda, and Saphris) require a trial of ALL preferred agents at max doses. *Typical antipsychotics do not required prior authorization.* Dosage limits apply: ABILIFY <13 years of age: 23mg/day ABILIFY ≥13 years of age: 45mg/day GEODON ≤ 17 years of age: 180mg/day GEODON > 17 years of age: 300mg/day INVEGA all ages: 18mg/day Risperidone ≤ 17 years of age: 5mg/day Risperidone > 17 years of age: 24mg/day Olanzapine < 13 years of age: 15mg/day Olanzapine > 13 years of age: 30mg/day SEROQUEL <13 years of age: 600mg/day SEROQUEL 13-17 years of age: 900mg/day SEROQUEL > 17 years of age: 1200mg/day ***Latuda will be approved for female clients of child-bearing age.**	FANAPT LATUDA*** SAPHRIS SEROQUEL XR (use preferred)
	ABILIFY/ODT GEODON INVEGA INVEGA SUSTENNA olanzapine RISPERDAL CONSTA risperidone SEROQUEL** ZYPREXA RELPREVV			
	SPECIAL ATYPICAL ANTIPSYCHOTICS		Dosage limits apply: 1350mg/day	
	clozapine			
ANTIVIRALS, ORAL	**HERPES AGENTS**			valacyclovir (BRAND IS PREFERRED)
	acyclovir famciclovir **VALTREX***			
CHOLESTEROL	**BILE ACID SEQUESTRANT**		Trial and failure of ALL preferred agents greater than or equal to six (6) months in the last 12 months will be required before approval can be given for a non-preferred agent.	WELCHOL
	cholestyramine/light colestipol			
	INTESTINAL CHOLESTEROL ABSORPTION INHIBITOR			
	ZETIA			
	STATINS, LOW POTENCY		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. If client's current medication therapy is contraindicated with the preferred statin(s) due to a drug-drug interaction, a non-preferred agent may be obtained with a prior authorization.	ALTOPREV LESCOL/XL
	lovastatin pravastatin			
	STATINS, HIGH POTENCY		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. If client's current medication therapy is contraindicated with the preferred statin(s) due to a drug-drug interaction, a non-preferred agent may be obtained with a prior authorization.	CRESTOR LIVALO
	atorvastatin simvastatin			
	STATIN COMBINATIONS		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ADVICOR (use separate agents) amlodopine/atorvastatin (BRAND IS PREFERRED) CHOLESTIN PRAVIGARD SIMCOR VYTORIN (use separate agents)
	CADUET*			
	TRIGLYCERIDE LOWERING AGENTS		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ANTARA fenofibric FENOGLIDE LOVAZA TRILIPIX
	fenofibrate gemfibrozil TRICOR			

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at *http://wyequalitycare.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT GHS FOR QUESTIONS
CONTRACEPTIVES	**ORAL CONTRACEPTIVES**			amethia (BRAND IS PREFERRED) amethyst (BRAND IS PREFERRED) aranelle (BRAND IS PREFERRED) BEYAZ (PA required) camila (use preferred) camrese (BRAND IS PREFERRED) caziant (use preferred) cesia (use preferred) cyclafem (BRAND IS PREFERRED) FEMCON FE (PA required) GENERESS FE CHW (PA required) gianvi (BRAND IS PREFERRED) heather (use preferred) introvale (use preferred) leena (BRAND IS PREFERRED) LO LOESTRIN (PA required) loryna (BRAND IS PREFERRED) NATAZIA (PA required) necon 0.5/35, 1/35, 7/7/7 (BRAND IS PREFERRED) NECON 1/50 (use preferred) norethindrone/ethyinyl estradiol chew (PA required) norethindrone (use preferred) NORINYL 1/35 (use preferred) nortrel (BRAND IS PREFERRED) ocella (BRAND IS PREFERRED) ORTHO-NOVUM 1/50 (use preferred) quasense (use preferred) SAFYRAL (PA required) syeda (BRAND IS PREFERRED) tilia FE (BRAND IS PREFERRED) tri-legest FE (BRAND IS PREFERRED) tri-lo-sprintec (BRAND IS PREFERRED) zarah (BRAND IS PREFERRED) zenchent FE chewable (PA required) zeosa chewable (PA required)
	altavera apri aviane azurette balzia **BREVICON*** briellyn cryselle emoquette enpresse errin **ESTROSTEP FE*** gildess FE jolessa jolivette junel/junel FE kariva kelnor lessina LOESTRIN 24 FE LOSEASONIQUE low-ogestrel lutera LYBREL microgestin mononessa NECON 10/11-28 nora-be norgestrel/ethinyl estradiol NORINYL 1/50-28 OGESTREL orsythia **ORTHO TRI-CYCLEN LO*** **ORTHO-NOVUM 1/35-28, 7/7/7-28*** OVCON 50 portia previfem reclipsen seasonale **SEASONIQUE*** solia sprintec sronyx trinessa **TRI-NORINYL*** tri-previfem trivora velivet **YASMIN*** **YAZ*** zenchent ZOVIA			
CORTICOSTEROIDS	**ORAL CORTICOSTEROIDS**			CELESTONE (use preferred)
	budesonide cortisone acetate dexamethasone/intensol hydrocortisone methylprednisone prednisolone prednisone			
COUGH AND COLD	**COMBINATION AGENTS**		Refer to the Over the Counter Drug Coverage at www.wyequalitycare.org for a list of covered products.	
	BROMFED DM			
	DEXTROMETHORPHAN AGENTS			
	DELSYM			
	GUAIFENESIN AGENTS			
	guaifenesin MUCINEX TAB 1200MG MUCINEX TAB 600MG ER MUCINEX CGH LIQ 5-100MG MUCINEX/KIDS GRA 100MG			

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at *http://wyequalitycare.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES (THIS LIST IS NOT ALL INCLUSIVE. PLEASE CONTACT GHS FOR QUESTIONS)
DIABETES	**DIABETES AGENTS**			FORTAMET (use preferred) GLUMETZA (use preferred) RIOMET (use preferred)
	BIGUANIDES			
	metformin/ER			
	α–GLUCOSIDASE INHIBITORS		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	GLYSET
	acarbose			
	MEGLITINIDES		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	nateglinide (BRAND IS PREFERRED) PRANDIN
	STARLIX*			
	THIAZOLIDINEDIONES		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ACTOSPLUS MET (use separate agents) AVANDIA AVANDAMET (use separate agents)
	ACTOS			
	SULFONYLUREAS		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	glimepiride/ER glipizide/ER glyburide/ER			
	DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent.	
		JANUVIA ONGLYZA TRADJENTA		
	DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITOR COMBO AGENTS		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent.	
		JANUMET JUVISYNC KOMBIGLYZE		
	INCRETIN MIMETICS (GLP-1 RECEPTOR AGONISTS)		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a **preferred agent**. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	VICTOZA
		BYETTA		
	INTERMEDIATE-ACTING INSULIN			
	HUMULIN N HUMULIN 70/30 NOVOLOG N NOVOLOG 70/30			
	LONG-ACTING INSULIN			LANTUS OPTICLIK/SOLOSTAR (use preferred) LEVEMIR (use preferred)
	LANTUS vial			
	RAPID-ACTING INSULIN			
	APIDRA HUMALOG NOVOLOG			
	DIABETIC METERS/TEST STRIPS		Quantity limit applies (1 meter/365days).	ALL OTHER METERS AND TEST STRIPS
	FREESTYLE LITE FREESTYLE FREEDOM LITE ONE TOUCH ULTRA ONE TOUCH ULTRA 2 ONE TOUCH ULTRA MINI ONE TOUCH ULTRASMART PRECISION XTRA			
EAR	**ANTIBIOTIC/STEROID COMBINATION**			CETRAXAL (use preferred) CIPRODEX (use preferred) CIPRO HC (use preferred) COLY-MYCIN S (use preferred) CORTISPORIN-TC (use preferred) dexamethasone sodium phosphate (use preferred) FLUOCINOLONE ACET OIL 0.01% (use preferred) Neomycin/Polymyxin B Sulfates/Hydrocortisone solution (BRAND IS PREFERRED)
	CORTISPORIN SOL 1% OTIC*			
	Neomycin/Polymyxin B Sulfates/Hydrocortisone suspension			
	ofloxacin			
FIBROMYALGIA	**FIBROMYALGIA STEP 1**			
	amitriptyline cyclobenzaprine			
	FIBROMYALGIA STEP 2		Trial and failure of a Step 1 agent greater than or equal to six (6) weeks in the last 12 months is required for approval of a Step 2 agent.	
		SAVELLA		
	FIBROMYALGIA STEP 3		Trial and failure of a Step 1 agent and a Step 2 agent greater than or equal to six (6) weeks in the last 12 months is required for approval of a Step 3 agent.	
		CYMBALTA LYRICA		

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at *http://wyequalitycare.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES (THIS LIST IS NOT ALL INCLUSIVE. PLEASE CONTACT GHS FOR QUESTIONS)
GASTROINTESTINAL	**DIGESTIVE ENZYMES**		Prior authorization required.	PANCREAZE
	CREON 3000, 6000, 12000, 24000 UNIT			pancrelipase (BRAND IS PREFERRED)
	ZENPEP*			TRI-PASE
	PROTON PUMP INHIBITORS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Lansoprazole solutabs will be approved for children less than or equal to 8 years of age. Lansoprazole capsules will be approved for children less than 1 year of age.	ACIPHEX lansoprazole NEXIUM omeprazole tablets (use preferred) omeprazole bicarbonate VIMOVO (use separate agents)
	DEXILANT omeprazole capsules pantoprazole			
	MESALAMINE		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	APRISO ASACOL/HD CANASA LIALDA PENTASA 500MG (use preferred) ROWASA
	mesalamine enema PENTASA 250MG ONLY			
GROWTH HORMONE	**GROWTH HORMONE**		PA is required for use outside of FDA-approved indications. Evaluation by an endocrinologist is preferred. Clinical evidence of improved growth will be required on a yearly basis to support ongoing utilization. Clinical evidence of need for growth hormone will be required for adult growth hormone deficiency and pediatric growth failure due to inadequate endogenous growth hormone. Trial and failure of two (2) preferred agents within the last 12 months will be required for the following indications: Pediatric: Growth failure due to inadequate endogenous growth hormone, Prader-Willi syndrome, children born small for gestation. Turner syndrome. Adult: Replacement for those with growth hormone deficiency.	HUMATROPE OMNITROPE SAIZEN SEROSTIM TEV-TROPIN ZORBTIVE
		GENOTROPIN NORDITROPIN NUTROPIN AQ		
HEPATITIS C	**INTERFERON**		Trial and failure of preferred agent greater than or equal to 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Peg-Intron will be approved for pediatric patients (aged 18 and under), for retreatment, and for dosage adjustments that cannot be achieved with Pegasys.	PEG-INTRON
	PEGASYS			
	PROTEASE INHIBITOR		Prior authorization required for non-preferred agent.	INCIVEK
	VICTRELIS			

WYOMING MEDICAID
Preferred Drug List (PDL) - JANUARY 1, 2012

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at *http://wyequalitycare.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES (THIS LIST IS NOT ALL INCLUSIVE. PLEASE CONTACT GHS FOR QUESTIONS)
IMMUNOMODULATORS	**IMMUNOMODULATORS**	ENBREL HUMIRA	Client must have ***diagnosis prior to approval*** for ***preferred agents*** *(outlined below)* : ***Enbrel*** : Ankylosing Spondylitis (AS), Juvenile Idiopathic Arthritis (JIA), Plaque Psoriasis (PP), Psoriatic Arthritis (PA), Rheumatoid Arthritis (RA)** ***Humira*** : AS, Crohn's, JIA, PP, PA, RA** **60-day trial and failure of methotrexate required prior to approval of Enbrel or Humira for diagnosis of Rheumatoid Arthritis (RA) For *non-preferred agents* , 60-day trial and failure of a preferred agent is required and client must have diagnosis prior to approval (outlined below): *Actemra* : RA (60-day trial of methotrexate is required) *Amevive* : PP *Cimzia* : Crohn's***, RA *Kineret* : RA *Orencia* : JIA, RA *Remicade* : AS, Crohn's, PP, PA, RA, Ulcerative Colitis**** *Rituxan* : RA *Simponi* : AS, PA, RA *Stelara* : PP *Tysabri : Crohn's (additional PA criteria applies)* ****Cimzia will be allowed without a preferred trial for diagnosis of Crohn's* *****Remicade will be allowed without a preferred trial for diagnosis of Ulcerative Colitis*	ACTEMRA AMEVIVE CIMZIA KINERET ORENCIA RAPTIVA REMICADE RITUXAN SIMPONI STELARA TYSABRI (additional criteria applies)
INSOMNIA	**NON-BENZODIAZEPINES**		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Rozerem is non-preferred without a history of substance abuse. Dosage limits apply: zaleplon: 30mg/day zolpidem: 15mg/day	EDLUAR (additional criteria applies) LUNESTA ROZEREM zolpidem ER ZOLPIMIST (additional criteria applies)
	zaleplon zolpidem			
MIGRAINE	**TRIPTAN STEP 1**		Quantity limits apply: naratriptan 1mg: 25tabs/34days naratriptan 2.5mg: 10tabs/34days sumatriptan kit: 3kits/34days sumatriptan vials: 2vials/34days sumatriptan nasal: 6bottles/34days sumatriptan 25mg: 41tabs/34days sumatriptan 50mg: 20tabs/34days sumatriptan 100mg: 10tabs/34days	AXERT FROVA MAXALT RELPAX TREXIMET ZOMIG
	naratriptan sumatriptan			
	TRIPTAN STEP 2		Trial and failure of a Step 1 agent greater will be required for approval of a Step 2 agent. Trial and failure of a Step 1 agent and a Step 2 agent will be required for approval of a non-preferred agent. Quantity limits apply: MAXALT MLT 5mg: 27tabs/34days MAXALT MLT 10mg: 14tabs/34days	
		MAXALT MLT		
MULTIPLE SCLEROSIS	**IMMUNOMODULATOR (GLATIRAMER INJECTION)**		Trial and failure of one (1) interferon agent AND failure of Copaxone before approval can be give for a non-preferre agent. For Tysabri, in addition to the above criteria, additional prior authorization criteria applies.	EXTAVIA GILENYA TYSABRI (additional criteria applies)
	COPAXONE			
	INTERFERON BETA-1A			
	AVONEX REBIF			
	INTERFERON BETA-1B			
	BETASERON			

WYOMING MEDICAID
Preferred Drug List (PDL) - JANUARY 1, 2012

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at *http://wyequalitycare.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES (THIS LIST IS NOT ALL INCLUSIVE. PLEASE CONTACT GHS FOR QUESTIONS)
NSAIDS	**NSAIDs**		Trial and failure of two (2) preferred agents each greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Dosing limits apply for ketorolac (limit 5days/34 days).	CALDOLOR CAMBIA POWDER CELEBREX FLECTOR (additional criteria applies) NAPRELAN NEOPROFEN PENNSAID (additional criteria applies) SOLARAZE (additional criteria applies) SPRIX (additional criteria applies) VOLTAREN (additional criteria applies) ZIPSOR
	diclofenac etodolac fenoprofen flurbiprofen ibuprofen indomethacin ketoprofen ketorolac meclofenamate meloxicam nabumetone naproxen oxaprozin sulindac tolmetin			
OPHTHALMICS	**OP. -ANTIBIOTICS- QUINOLONES**		Trial and failure of a preferred agent greater than or equal to 5 days in the last 12 months will be required before approval can be given for a non-preferred agent. Azasite will be approved for pregnancy.	AZASITE BESIVANCE IQUIX levofloxacin MOXEZA ZYMAR ZYMAXID
	ciprofloxacin ofloxacin VIGAMOX			
	OP. -ANTI-INFLAMMATORY- NSAIDS		Trial and failure of ALL preferred agents each greater than or equal to 5 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ACULAR/LS/PF (use preferred) ACUVAIL BROMDAY bromfenac NEVANAC
	flurbiprofen diclofenac ketorolac			
	OP. -BETA-BLOCKERS		Trial and failure of three (3) preferred agents each greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Betoptic S will be approved for those with heart and lung conditions.	BETIMOL BETOPTIC S ISTALOL
	betaxolol carteolol levobunolol metipranolol timolol			
	OP. -CARBONIC ANHYDRASE INHIBITOR		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	AZOPT
	dorzolamide			
	OP. -CARBONIC ANHYDRASE INHIBITOR COMBO		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	
	dorzolamide/timolol			
OPHTHALMICS *Continued*	**OP. -MAST CELL STABILIZERS STEP 1**		Trial and failure of a Step 1 agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a Step 2 agent. Trial and failure of a Step 1 agent and a Step 2 agent greater than or equal to 30 days in the last 12 months will be required for approval of a non-preferred agent. Emadine, Alomide, and Alocril will be approved for pregnancy.	ALAMAST ALOCRIL ALOMIDE ALREX azelastine BEPREVE ELESTAT EMADINE ketotifen LASTACAFT
	cromolyn			
	OP. -MAST CELL STABILIZERS STEP 2			
		PATADAY PATANOL		
	OP. -PROSTAGLANDINS		Trial and failure of ALL preferred agents each greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	LUMIGAN
	latanoprost TRAVATAN Z			
	OP. -SYMPATHOMIMETICS		Trial of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	COMBIGAN (use separate agents)
	ALPHAGAN P brimonidine dipivefrin			
OSTEOPOROSIS	**BISPHOSPHONATES**		Trial and failure of a preferred agent greater than or equal to 12 months will be required before approval can be given for a non-preferred agent. Fosamax liquid will be approved for clients that have difficulty swallowing.	ACTONEL ATELVIA BONIVA FOSAMAX-D
	alendronate			
	NASAL CALCITONIN			
	calcitonin-salmon fortical			

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at *http://wyequalitycare.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES (THIS LIST IS NOT ALL INCLUSIVE. PLEASE CONTACT GHS FOR QUESTIONS)
OVERACTIVE BLADDER	**OVERACTIVE BLADDER AGENTS**		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Oxytrol will be approved for clients that have an inability to swallow.	DETROL/LA ENABLEX GELNIQUE GEL 10% OXYTROL DIS SANCTURA XR trospium
	oxybutynin /ER TOVIAZ VESICARE			
PHOSPHATE BINDERS	**PHOSPHATE BINDERS**		Prior authorization required for non-preferred agents.	FOSRENOL RENVELA
	calcium acetate **ELIPHOS*** **PHOSLO*** **PHOSLYRA** RENAGEL			
PRENATAL VITAMINS	**PRENATAL VITAMINS**		Prenatal vitamins containing Omega-3 and DHA will be approved for clients at high risk for pre-term labor.	ALL OTHER PRENATAL VITAMINS INCLUDING OVER-THE-COUNTER FORMULATIONS
	BP MULTINATL TAB PLUS COMPLETE-RF CO-NATAL FA ELITE-OB FOLIVANE-OB INATAL ULTRA LACTOCAL-F MARNATAL-F MAXINATE NATAFORT O-CAL PRENAFIRST PRENAPLUS PRENATABS RX PRENATAL 19/CHEWABLE PRENATAL LOW IRON PRENATAL PLUS/FE SE-CARE/CHEWABLE SELECT-OB CHEWABLE SE-NATAL 19/CHEWABLE SE-NATAL 90 SE-NATAL ONE TARON-BC TARON-EC CAL TRIMESIS RX TRINATAL RX TRINATE TRI RX TRIVEEN-U VINATE II VINATE AZ VINATE C VINATE CAL VINATE IC VINATE M VINATE ONE VINATE ULTRA VITASPIRE VOL-TAB RX VOL-PLUS			
PROSTATE	**5-ALPHA-REDUCTASE INHIBITORS**		Trial and failure of a preferred agent greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	AVODART JALYN (use separate agents)
	finasteride			
	ALPHA BLOCKERS		Trial and failure of a preferred agent greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	alfuzosin JALYN (use separate agents) RAPAFLO
	doxazosin tamsulosin terazosin			
PULMONARY ANTIHYPERTENSIVES	**5-ALPHA-REDUCTASE INHIBITORS**		Client must have a diagnosis of pulmonary hypertension.	
		ADCIRCA REVATIO		
	ENDOTHELIN RECEPTOR ANTAGONISTS		Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	TRACLEER
		LETAIRIS		
RESTLESS LEG SYNDROME	**RESTLESS LEG SYNDROME**		Client must have a diagnosis of Restless Leg Syndrome (RLS). Trial and failure of gabapentin greater than or equal to 60 days and a trial and failure of a dopamine agonist greater than or equal to 60 days in the last 12 months will be required before approval can be given for a non-preferred agent.	HORIZANT
		gabapentin		

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at *http://wyequalitycare.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES (THIS LIST IS NOT ALL INCLUSIVE. PLEASE CONTACT GHS FOR QUESTIONS)
SKELETAL MUSCLE RELAXANTS	**MUSCLE RELAXANTS**		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months, along with a medical diagnosis of muscle spasticity will be required before approval can be given for a non-preferred agent.	carisoprodol chlorzoxazone cyclobenzaprine ER metaxalone methocarbamol orphenadrine Carisoprodol is limited to 84 tabs/365 days.
	baclofen cyclobenzaprine tizanidine			
STIMULANTS	**AMPHETAMINES**		Clients must have a diagnosis for ADD, ADHD, narcolepsy, obstructive sleep apnea, shift work sleep disturbance, MS fatigue (see MS Fatigue criteria below), or refractory depression (see refractory depression criteria below). Diagnosis of MS fatigue will require a fatigue severity scale score of 5.0, a 60-day trial of amantadine and discontinuation of medications that may contribute to drowsiness and fatigue. Diagnosis of refractory depression will require a 6-week trial and failure of an antidepressant (monotherapy) and continued concomitant use of an antidepressant with the stimulant. Prior Authorization will be required for clients under the age of 5. Claims will require Prior Authorization if clients have a history of the following: glaucoma, cardiac arrhythmias, arteriosclerosis, untreated hypertension, untreated hyperthyroidism, substance abuse, or current MAO inhibitor use. Trial and failure of two (2) preferred agents (each from a different class: methylphenidate and amphetamine) greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. ***Strattera is limited to 1 tablet/day; unless the dose is greater than 40mg/day or unable to achieve a prescribed dose with 1 tablet.*** **Quantity limits apply:** **ADDERALL XR: 60mg/day** **amphetamine salts combo: 60mg/day** **amphetamine salts combo (narcolepsy): 90mg/day** **CONCERTA: 135mg/day** **DAYTRANA: 45mg/9 hour patch** **dextroamphetamine: 90mg/day** **dextroamphetamine CR: 90mg/day** **dexmethylphenidate: 30mg/day** **FOCALIN XR ≤ 13 years of age: 45mg/day** **FOCALIN XR > 13 years of age: 60mg/day** **methylin/methylphenidate: 135mg/day** **methylin/methylphenidate ER/CR/SR: 135mg/day** **VYVANSE: 105mg/day**	**AMPHETAMINES:** amphetamine salts combo ER (BRAND IS PREFERRED) **METHYLPHENIDATES:** METADATE CD RITALIN LA
	LONG ACTING AMPHETAMINES			
		ADDERALL XR*		
		VYVANSE		
		dextroamphetamine CR		
	IMMEDIATE RELEASE AMPHETAMINES			
		amphetamine salts combo		
		dextroamphetamine		
	METHYLPHENIDATES			
	LONG ACTING METHYLPHENIDATES			
		DAYTRANA		
		FOCALIN XR		
		methylin ER		
		methylphenidate ER/CR/SA/SR		
	IMMEDIATE RELEASE METHYLPHENIDATES			
		FOCALIN		
		methylin tablets		
		methylphenidate		
STIMULANTS *Continued*	**SELECTIVE ALPHA-ADRENERGIC AGONIST**		To obtain the **non-preferred agent**, client must meet the following criteria: Client must have a diagnosis of ADHD or ADD. Prior authorization will be required for clients under the age of 5. Client must have a trial and failure of a stimulant greater than or equal to a 14 OR a trial and failure of Strattera greater than or equal to a 30 day supply **AND** trial and benefit of guanfacine (Tenex) in the previous 12 months OR a contraindication to ADHD medications (including stimulant and non-stimulant) OR a TIC disorder associated with stimulants (trial of stimulant required).	INTUNIV
	GUANFACINE AGENTS			
	guanfacine			
	CLONIDINE AGENTS		Trial and benefit of clonidine IR will be required prior to approval of the non-preferred agent.	KAPVAY
	clonidine			

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at *http://wyequalitycare.org* for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES (THIS LIST IS NOT ALL INCLUSIVE. PLEASE CONTACT GHS FOR QUESTIONS)
TOPICAL AGENTS	**IMPETIGO ANTIBIOTICS**		Trial and failure of ALL preferred agents greater than or equal to 7 days in the past 90 days. Use smallest size appropriate for 7 day trial.	ALTABAX
	gentamicin mupirocin			
	BENZOYL PEROXIDE/CLINDAMYCIN COMBOs		Clients must be 12 to 20 years of age and have a diagnosis of acne vulgaris. Requires prior authorization for clients less than 12 years of age. Acne combinations are limited to clients under the age of 21.	ACANYA
		benzoyl peroxide/clindamycin		
	CORTICOSTEROIS C=CREAM; G=GEL; L=LOTION; O=OINTMENT		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	PANDEL
	LOW POTENCY			
	alclometasone desonide fluocinolone 0.01% hydrocortisone butyrate 0.1% (C) hydrocortisone 1%, 2.5% (C,L,O) prednicarbate			
	MEDIUM POTENCY		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	CLODERM CORDRAN/SP TOPICORT LP TRIANEX
	betamethasone valerate desoximetasone 0.05% (C) fluocinolone 0.025% fluticasone 0.05% (C) hydrocortisone butyrate 0.1% (O) hydrocortisone probutate 0.1% (C) mometasone triamcinolone 0.025%, 0.1%			
	HIGH POTENCY		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	HALOG
	amcinonide betamethasone dipropionate clobetasol desoximetasone 0.25%, 0.05% (G) diflorasone fluocinonide flurandrenolide fluticasone 0.005% (O) halobetasol triamcinolone 0.5%			
	IMMUNOMODULATORS		Trial and failure of a preferred medium potency topical corticosteroid greater than or equal to a 21 day trial and a trial and failure of a preferred high potency topical corticosteroid greater than or equal to a 21 day trial in the last 90 days.	
		ELIDEL PROTOPIC		
	SALICYLIC ACID			All other topical salicylic acid formulations.
	aliclen shampoo 6% salacyn cream/lotion 6% Salicylic Acid Shampoo 6%			
	SCABICIDES/PEDICULICIDES		Trial and failure of a preferred agent in the last 12 months.	NATROBA OVIDE ULESFIA
	permethrin LINDANE			
	UREA			All other topical urea formulations.
	Kerafoam Aerosol 30% Remeven Cream 50% urea hydration aerosol 35% urea emulsion 50% urea nail suspension 40% urea suspension 50% X-Viate Cream 40%			

WYOMING MEDICAID

ADDITIONAL THERAPEUTIC CLASSES WITH CLINICAL CRITERIA

Unless otherwise noted, generic substitution is mandatory

Last Updated 1/12

THERAPEUTIC CLASS	DRUG NAME	CLINICAL CRITERIA
ANTICONVULSANTS		
	gabapentin	Client must have gabapentin on file in the previous 90 days **OR** a diagnosis of chronic pain, epilepsy, neuropathic pain, postherpetic neuralgia, vasomotor symptoms due restless leg syndrome, to menopause or vasomotor symptoms due to prostate cancer in the last 12 months.
	lamotrigine	Client must have lamotrigine on file in the previous 90 days **OR** a diagnosis of epilepsy, bipolar, mood disorder or schizoaffective disorder in the last 12 months.
	levetiracetam	Client must have levetiracetam on file in the previous 90 days **OR** a diagnosis of epilepsy in the last 12 months.
	LYRICA	Client must have Lyrica on the file in the previous 90 days **OR** a diagnosis of epilepsy, cancer, or history of antineoplastic therapy in the last 12 months. A 6-week trial of amitriptyline **OR** cyclobenzaprine **AND** Savella will be required if the client has a diagnosis of fibromyalgia. A trial and failure of gabapentin greater than or equal to 30 days is required if the client has a diagnosis of neuropathic pain associated with diabetes, neuropathies or postherpetic neuralgia in the last 12 months.
	oxcarbazepine	Client must have oxcarbazepine on the file in the previous 90 days **OR** a diagnosis of epilepsy, bipolar or unspecified mood disorders in the last 12 months.
	topiramate	Client must have topiramate on file in the previous 90 days **OR** a diagnosis of epilepsy or migraines in the last 12 months.
	zonisamide	Client must have zonisamide on file in the previous 90 days **OR** a diagnosis of epilepsy in the last 12 months.
ACNE COMBINATIONS		
Clindamycin Phosphate-Tretinoin Gel	**VELTIN**	Client must use separate agents. Acne products are limited to clients ≤ 20 years of age.
	ZIANA	Client must use separate agents. Acne products are limited to clients ≤ 20 years of age.
ANTIHYPERTENSIVES LONG ACTING		
	ANTIHYPERTENSIVES LONG ACTING	Limited to labeled dosing frequency. Exceptions will be made with prior authorization for electrophysiology and use in akathesia.
ATYPICAL ANTIPSYCHOTICS		
	SEROQUEL	Doses less than 100mg will require prior authorization without a diagnosis of mood disorder or major depressive disorder. For titration doses, contact the GHS Pharmacy Help Desk for an override.
BOTOX AGENTS		
	BOTOX	Client must have diagnosis of cervical dystonia (spasmodic torticollis), strabismus and blepharospasm associated with dystonia, spasmodic dystonia (laryngeal dystonia), spasmodic dysphonia, hand dystonia (writer's, musician's, or typist's cramp), torsion dystonia, tongue dystonia, hand tremor, voice tremor, spasticity associated with cerebral palsy, stroke, multiple sclerosis, chronic anal fissure, achalasia, hyperhidrosis including gustatory sweating (frey's syndrome), piriformis syndrome, hemifacial spasm, sialorrhea, detrusor-sphincter dyssynergia, oromandibular dystonia, migraine prophylaxis, or urinary incontinence due to detrusor overactivity associated with a neurologic condition in adults who have inadequate response to or are intolerant of an anticholinergic medication. The following additional criteria will be required before approval will be given to clients with the diagnosis of primary hyperhidrosis: a 6-month trial and failure of topical dermatologics (i.e.. Aluminum chloride, tannic acid, glutaraldehyde, anticholinergics), systemic anticholinergics, tranquilizers, or NSAIDS **AND** prescription strength antiperspirants.
	DYSPORT	Client must have diagnosis of cervical dystonia (spasmodic torticollis).
	MYOBLOC	Client must have diagnosis of cervical dystonia (spasmodic torticollis).
	XEOMIN	Client must have diagnosis of cervical dystonia (spasmodic torticollis) **OR** diagnosis of blepharospasm and a 30 day trial and failure of Botox.
CHRONIC OBSTRUCITVE PULMONARY DISEASE (COPD) AGENTS		
	ARCAPTA	Client must be > 40 years of age and have a diagnosis of COPD
	DALIRESP	Requires adjunct therapy for COPD which must include at least one long-acting anti-muscarinic.
FENTANYL SHORT-ACTING		
	ABSTRAL	Client must be ≥ 16 years of age **AND** have a diagnosis of malignant cancer or received antineoplastic therapy in the last 12 months. Limited to labeled dose frequency.
	ACTIQ	Client must be ≥ 16 years of age **AND** have a diagnosis of malignant cancer or received antineoplastic therapy in the last 12 months. Limited to labeled dose frequency.
	FENTORA	Client must be ≥ 16 years of age **AND** have a diagnosis of malignant cancer or received antineoplastic therapy in the last 12 months. Limited to labeled dose frequency.
	LAZANDA	Client must be ≥ 16 years of age **AND** have a diagnosis of malignant cancer or received antineoplastic therapy in the last 12 months. Limited to labeled dose frequency.
	ONSOLIS	Client must have a diagnosis of breakthrough cancer pain **AND** a trial and failure of fentanyl transmucosal and buccal tablets greater than or equal to a 14 day supply in the last 12 months. Limited to labeled dose frequency.
SEX HORMONES		
	Chorionic Gonadotropin	Client must have a diagnosis of prepubertal cryptorchidism or hypogonadism in the last 12 months.
	leuprolide	Client must have a diagnosis of prostate cancer, endometriosis, uterine leiomyomata or central precocious puberty in the last 12 months.
	NOVAREL	Client must have a diagnosis of prepubertal cryptorchidism or hypogonadism in the last 12 months.
	PLENAXIS	Client must have diagnosis of prostate cancer in the last 12 months.
	SUPPRELIN LA	Client must have diagnosis of prostate cancer or central precocious puberty in the last 12 months
	SYNAREL	Client must have diagnosis of central precocious puberty or endometriosis in the last 12 months.
	TRELSTAR	Client must have diagnosis of prostate cancer in the last 12 months.

WYOMING MEDICAID
ADDITIONAL THERAPEUTIC CLASSES WITH CLINICAL CRITERIA
Unless otherwise noted, generic substitution is mandatory
Last Updated 1/12

THERAPEUTIC CLASS	DRUG NAME	CLINICAL CRITERIA
SEX HORMONES *continued*	VANTAS	Client must have diagnosis of prostate cancer or central precocious puberty in the last 12 months.
	ZOLADEX	Client must have diagnosis of prostate cancer, breast cancer, endometrial thinning or endometriosis in the last 12 months.
VACCINES		
	CERVARIX	Approved for clients ≥ 19 years of age. Clients < 19 years of age refer to the immunization program at 307-777-7952.
	GARDASIL	Approved for clients ≥ 19 years of age. Clients < 19 years of age refer to the immunization program at 307-777-7952.
VERSA FOAM AGENTS		
	clobetasol propionate (foam)	Trial and failure of 2 other dosage forms greater than or equal to a 14 day supply in the last 12 months **OR** a diagnosis of scalp psoriasis or alopecia areata will be required prior to approval.
	clindamycin (aerosol)	Trial and failure of 2 other dosage forms greater than or equal to a 14 day supply in the last 12 months **OR** a diagnosis of scalp psoriasis or alopecia areata will be required prior to approval.
	EXTINA	Trial and failure of 2 other dosage forms greater than or equal to a 14 day supply in the last 12 months **OR** a diagnosis of scalp psoriasis or alopecia areata will be required prior to approval.
	LUXIQ	Trial and failure of 2 other dosage forms greater than or equal to a 14 day supply in the last 12 months **OR** a diagnosis of scalp psoriasis or alopecia areata will be required prior to approval.
	OLUX-E	Trial and failure of 2 other dosage forms greater than or equal to a 14 day supply in the last 12 months **OR** a diagnosis of scalp psoriasis or alopecia areata will be required prior to approval.
	SALKERA	Trial and failure of 2 other dosage forms greater than or equal to a 14 day supply in the last 12 months **OR** a diagnosis of scalp psoriasis or alopecia areata will be required prior to approval.
	VERDESO	Trial and failure of 2 other dosage forms greater than or equal to a 14 day supply in the last 12 months **OR** a diagnosis of scalp psoriasis or alopecia areata will be required prior to approval.
MISC.		
	alprazolam ODT	Client must use alprazolam.
	AMTURNIDE	Client must use separate agents.
	AMPYRA	Client must have a diagnosis of a gait disorder associated with Multiple Sclerosis. Initial use will be allowed for three months. After three months, the prescriber will have to certify that the drug is effective for the patient for continued therapy.
	ATOPICLAIR	Approved for children < 5 years of age.
	BRILINTA	Approved for clients with acute coronary syndrome to reduce thrombotic cardiovascular events.
	CIALIS	A ninety (90) day trial and failure each, of ALL other medications for benign prostatic hyperplasia (BPH) will be required before Cialis will be approved to treat BPH. Wyoming Medicaid DOES NOT cover Cialis to treat erectile dysfunction (ED).
	dronabinol	Client must have a diagnosis of AIDS or Cancer. Dosage limits apply.
	FIRAZYR	Requires prior authorization (PA). Approved for the treatment of acute attacks of hereditary angioedema.
	FRESHKOTE	Requires a 14 day trial and failure of two different over-the-counter agents consisting of at least one artificial tear & lubricant product. The trial should also consist of two separate types of agents. If possible, the trial should include Murine Tears for Dry Eyes as this is the most closely related OTC product to FreshKote.
	GRALISE	Requires a 60 day trial and **documented response** to immediate release gabapentin with a credible reason for the need of the once daily formulation. The dose will be limited to 1800mg/day.
	INTUNIV	Client must have a diagnosis of ADHD or ADD. Prior authorization will be required for clients under the age of 5. Client must have a trial and failure of a stimulant greater than or equal to a 14 day supply **OR** a trial and failure of Strattera greater than or equal to a 30 day supply **AND** a 14 day trial and benefit of guanfacine (Tenex) in the previous 12 months **OR** a contraindication to ADHD medications (including stimulant and non-stimulant) **OR** a TIC disorder associated with stimulants (trial of stimulant required).
	LIDODERM PATCHES	Client must have a diagnosis of peripheral neuropathy or postherpetic neuralgia.
	LYSTEDA	Trial and failure of an oral contraceptive or progesterone only hormone replacement AND one NSAID greater than or equal to a 90 day supply in the last 12 months will be required prior to approval.
	MOXATAG	Client must use amoxicillin.
	MULTAQ	Client must use amiodarone.
	NUEDEXTA	Client must have diagnosis of Pseudobulbar Affect.
	NUVIGIL	Trial and failure of Provigil greater than or equal to a 14 day supply in the last 12 months will be required prior to approval.
	ondansetron	Clients ≤ 11 will be allowed a one (1) day supply every 30 days unless they have a diagnosis of cancer. No limits for clients ≥ 12.
	ORAVIG	Client must have diagnosis of oral candidiasis **AND** head/neck cancer or HIV.
	ORBIVAN	Trial and failure of **ALL** butalbital containing agents, the max dose of acetaminophen ***and*** the max dose of a preferred NSAID. For the treatment of migraine headache, ALL preferred migraine agents must also be tried in addition to the butalbital, APAP, and NSAID trials.
	promethazine	Approved for clients ≥ 3 years of age.
	PROVIGIL	Client must be ≥ 16 years of age. Client must have a diagnosis of narcolepsy, obstructive sleep apnea, shift work sleep disorder or Multiple Sclerosis (MS) Fatigue. Diagnosis of MS will require a fatigue severity scale score of 5.0, a 60 day trial of amantadine **AND** discontinuation of medications that may contribute to drowsiness or fatigue.

WYOMING MEDICAID

ADDITIONAL THERAPEUTIC CLASSES WITH CLINICAL CRITERIA

Unless otherwise noted, generic substitution is mandatory

Last Updated 1/12

THERAPEUTIC CLASS	DRUG NAME	CLINICAL CRITERIA
MISC. *continued*		
	QUALAQUIN	Client must have a history of malaria in the past 6 months.
	RIBAPAK	Must use individual ribavirin tablets.
	SOLODYN	Client must use minocycline ER.
	STRATTERA	Clients must have a diagnosis for ADD, ADHD, narcolepsy, obstructive sleep apnea, shift work sleep disturbance, MS fatigue (see MS Fatigue criteria below), or refractory depression (see refractory depression criteria below). Diagnosis of MS fatigue will require a fatigue severity scale score of 5.0, a 60-day trial of amantadine and discontinuation of medications that may contribute to drowsiness and fatigue. Diagnosis of refractory depression will require a 6-week trial and failure of an antidepressant (monotherapy) and continued concomitant use of an antidepressant with the stimulant. Prior Authorization will be required for clients under the age of 5. Claims will require Prior Authorization if clients have a history of the following: glaucoma, cardiac arrhythmias, arteriosclerosis, untreated hypertension, untreated hyperthyroidism, substance abuse, or current MAO inhibitor use. Dosing limits apply (150% of labeled max). Limited to 1 tablet/day; unless dose is greater than 40mg/day or unable to achieve prescribed dose with 1 tablet.
	SYNAGIS	Requires prior authorization (PA). Max of 5 doses per season at a dosing interval greater than or equal to 28 days. Client must meet the following criteria: **Chronic Lung Disease:** Client is ≤ 24 months of age at start of therapy and has chronic lung disease of prematurity requiring medication or oxygen within 6 months of the start of RSV season. ***OR*** **Congenital Heart Disease:** Client is ≤ 24 months of age at start of therapy and has hemodynamically significant congenital heart disease and one or more of the following: *Is receiving medication to control congestive heart failure *Has a diagnosis of moderate to severe pulmonary hypertension *Has a diagnosis of cyanotic heart disease ***OR*** **Prematurity:** *Client is ≤ 12 months of age at start of RSV season and born at ≤ 28 weeks, 6 days gestational age *Client is ≤ 12 months of age at start of RSV season and born at 34 weeks, 6 days gestational age and has either severe neuromuscular disease or congenital abnormalities, either of which compromise handling of respiratory secretions *Client is ≤ 6 months of age at the start of the RSV season and born between 29weeks, 0 days and 35 weeks, 6 days gestational age
	TEKAMLO	Client must use separate agents.
	ULORIC	Trial and failure of allopurinol greater than or equal to a 90 day supply in the last 12 months will be required prior to approval.
	XERESE	Client must use separate agents.
	XIFAXAN	Xifaxan 200mg - Client must have a diagnosis of traveler's diarrhea. Xifaxan 550mg - Client must be ≥ 18 years of age and have a diagnosis of reduction in risk of overt hepatic encephalopathy recurrence.
	XOLAIR	Trial and failure of Salmeterol, Formoterol, Albuterol, Theophylline SR, Singulair, or Accolate **AND** a trial and failure of Qvar, Pulmicort Turbuhaler, Aerobid, Azmacort, or Flovent at maximum doses in the last 30 days will be required prior to approval.
	ZYTIGA	Client must have a diagnosis of castration-resistant prostate cancer and have received prior chemotherapy containing docetaxel.
TOPICAL AGENTS		
	ZYCLARA	Trial and failure of imiquimod greater than or equal to 28 days in the last 12 months will be required before approval can be given for a non-preferred agent.
	TAZORAC	Allowed for clients with the diagnosis of psoriasis for all ages. For the treatment of acne vulgaris, acne combinations are limited to those clients < 21.

DOSAGE LIMITATION LIST

(*) Indicates BRAND is Preferred

If the Brand name is underlined a generic is currently not available

Last Updated January 1, 2012

Brand Name	Generic Name	Strength	Limit/Day	Limit/Days
ABILIFY (<13 YEARS OF AGE)	ARIPIPRAZOLE (<13 YEARS OF AGE)		23 MG	
ABILIFY (>=13 YEARS OF AGE)	ARIPIPRAZOLE (>=13 YEARS OF AGE)		45 MG	
ADDERALL	AMPHETAMINE SALTS/D-AMPHETAMINE SALTS		60 MG	
			90 MG	(for diagnosis of narcolepsy)
ADDERALL XR *	AMPHETAMINE SALTS/D-AMPHETAMINE SALTS		60 MG	
ADVAIR (7 & 14 DAY PACKS)	FLUTICASONE/SALMETEROL			1/365
AMBIEN (IR)	ZOLPIDEM (IR)		15 MG	
AMBIEN CR	ZOLPIDEM CR		18.75 MG	
AMERGE	NARATRIPTAN	1 MG		25/34
AMERGE	NARATRIPTAN	2.5 MG		10/34
ANTIHYPERTENSIVES, LONG ACTING				LABELED FREQUENCY
AXERT	ALMOTRIPTAN	6.25 MG		27/34
AXERT	ALMOTRIPTAN	12.5 MG		27/34
CATHETERS			10 CATHETERS	
CHANTIX	VARENICLINE			168 tabs &/or 84 days/365
CLOZARIL	CLOZAPINE		1350 MG	
CONCERTA*	METHYLPHENIDATE		135 MG	
CYMBALTA	DULOXETINE		120 MG	
DARVON	PROPOXYPHENE		6 TABS	
DAYTRANA	METHYLPHENIDATE		45MG/9HR PATCH	
DEXEDRINE/DEXTROSTAT	D-AMPHETAMINE		90 MG	
DIABETIC MONITOR				1/365
DIABETIC LANCET DEVICE				1/365
DURAGESIC PATCH	FENTANYL PATCH			1 PATCH/72 HOURS
FANAPT	ILOPERIDONE		36 MG	
FAZACLO	CLOZAPINE		1350MG	
FOCALIN *	DEXMETHYLPHENIDATE		30 MG	
FOCALIN XR (<=13 YEARS OF AGE)	DEXMETHYLPHENIDATE		45 MG	
FOCALIN XR (>13 YEARS OF AGE)	DEXMETHYLPHENIDATE		60 MG	
FROVA	FROVATRIPTAN	2.5 MG		20/34
GEODON (<=17 YEARS OF AGE)	ZIPRASIDONE (<=17 YEARS OF AGE)		180 MG	
GEODON (>17 YEARS OF AGE)	ZIPRASIDONE (>17 YEARS OF AGE)		300 MG	
GRALISE	GABAPENTIN		1800 MG	
IMITREX KIT	SUMATRIPTAN KIT	6 MG/0.5 ML		3 KITS/34
IMITREX VIAL	SUMATRIPTAN VIAL	6 MG/0.5 ML		2 VIALS/34
IMITREX NASAL SPRAY	SUMATRIPTAN NASAL SPRAY	20 MG		6 BOTTLES/34
IMITREX TAB	SUMATRIPTAN TAB	25 MG		41/34
IMITREX TAB	SUMATRIPTAN TAB	50 MG		20/34
IMITREX TAB	SUMATRIPTAN TAB	100 MG		10/34
INCONTINENCE PRODUCTS	BRIEFS		13 BRIEFS	
	DIAPERS		13 DIAPERS	
	LINERS		13 LINERS	
	PADS		13 PADS	
INVEGA	PALIPERIDONE		18 MG	
IV EQUIPMENT				1/365
LUNESTA	EZOPICLONE		4.5 MG	
MARINOL	DRONABINOL		20 MG	

DOSAGE LIMITATION LIST

(*) Indicates BRAND is Preferred

If the Brand name is underlined a generic is currently not available

Last Updated January 1, 2012

Brand Name	Generic Name	Strength	Limit/Day	Limit/Days
MAXALT	RIZATRIPTAN	5 MG		27/34
MAXALT	RIZATRIPTAN	10 MG		14/34
MAXALT MLT	RIZATRIPTAN MLT	5 MG		27/34
MAXALT MLT	RIZATRIPTAN MLT	10 MG		14/34
METADATE CD/ER	METHYLPHENIDATE		90 MG	
METHYLIN/ER		135MG		
METHYLPHENIDATE/ER		135MG		
NEBULIZER				1/365
NICOTINE GUM				735 pcs &/or 84 days/365
NICOTINE LOZENGES				735 pcs &/or 84 days/365
NICOTINE PATCH		5 MG		14 PATCH &/or 14 DAYS/365
NICOTINE PATCH		7 MG		14 PATCH &/or 14 DAYS/365
NICOTINE PATCH		10 MG		14 PATCH &/or 14 DAYS/365
NICOTINE PATCH		14 MG		14 PATCH &/or 14 DAYS/365
NICOTINE PATCH		15 MG		84 PATCH &/or 84 DAYS/365
NICOTINE PATCH		21 MG		42 PATCH &/or 42 DAYS/365
NICOTINE TRANSDERMAL SYSTEM				56 PATCH &/or 56 DAYS/365
OXANDRIN	OXANDROLONE	2.5 MG	8 TABS	272/34
OXANDRIN	OXANDROLONE	10 MG	2 TABS	68/34
OXYCONTIN CR (Limit 2 strengths per client)	OXYCODONE ER (Limit 2 strengths per client)	ALL STRENGTHS	3 TABS/strength	102/34/strength (Limit 2 strengths per client)
PROSOM	ESTAZOLAM		3 MG	
RELPAX	ELETRIPTAN	20 MG		20/34
RELPAX	ELETRIPTAN	40 MG		14/34
RISPERDAL (<=17 YEARS OF AGE)	RISPERIDONE (<=17 YEARS OF AGE)		5 MG	
RISPERDAL (>17 YEARS OF AGE)	RISPERIDONE (>17 YEARS OF AGE)		24 MG	
RITALIN	METHYLPHENIDATE		135 MG	
RITALIN LA	METHYLPHENIDATE		90 MG	
RITALIN SR	METHYLPHENIDATE ER/METHYLIN ER		135 MG	
ROZAREM	RAMELTEON		12 MG	
RYZOLT	TRAMADOL		300 MG	
SAPHRIS	ASENAPINE		30 MG	
SEREVENT (14 DAY PACK)	SALMETEROL			1/365
SEROQUEL (<13 YEARS OF AGE)	QUETIAPINE FUMARATE (<13 YEARS OF AGE)		600 MG	
SEROQUEL (13-17 YEARS OF AGE)	QUETIAPINE FUMARATE (13-17 YEARS OF AGE)		900 MG	
SEROQUEL (>17 YEARS OF AGE)	QUETIAPINE FUMARATE (>17 YEARS OF AGE)		1200 MG	
SHARPS CONTAINER				1/365
SOMA	CARISOPRODOL			84/365
SONATA	ZALEPLON		30 MG	
SPACER				1/365
SPIRIVA (5 DAY PACK)	TIOTROPIUM BROMIDE			1/365
SPIROMETER				1/365
STADOL NASAL SPRAY	BUTORPHANOL	10 MG/ML		1 BOTTLE/34

DOSAGE LIMITATION LIST

(*) Indicates BRAND is Preferred

If the Brand name is underlined a generic is currently not available

Last Updated January 1, 2012

Brand Name	Generic Name	Strength	Limit/Day	Limit/Days
STRATTERA	ATOMOXETINE		150 MG	1 tab/day *Exception applies if dose is greater than 40mg/day or unable to achieve prescribed dose with 1 tablet.
SUBOXONE	BUPRENORPHONE/NALOXONE		24 MG	
SUBUTEX	BUPRENORPHONE		24 MG	
TALWIN NX	PENTAZOCINE/NALOXONE		2 TABS	60/30
TORADOL SYRINGE	KETOROLAC SYRINGE	30 MG		5-DAY DURATION/34 DAYS
TORADOL SYRINGE	KETOROLAC SYRINGE	15 MG		5-DAY DURATION/34 DAYS
TORADOL TAB	KETOROLAC TAB	10 MG		5-DAY DURATION/34 DAYS
TREXIMET	SUMATRIPTAN/NAPROXEN			10/34
ULTRAM	TRAMADOL		8 TABS	
ULTRAM ER	TRAMADOL ER	100 MG	300 MG	
ULTRAM ER	TRAMADOL ER	200 MG	300 MG	
ULTRAM ER	TRAMADOL ER	300 MG	300 MG	
ULTRACET	TRAMADOL/APAP		8 TABS	5-DAY DURATION/34 DAYS
VYVANSE	LISDEXAMFETAMINE		105 MG	
ZOMIG	ZOLMITRIPTAN	2.5 MG		20/34
ZOMIG	ZOLMITRIPTAN	5 MG		10/34
ZOMIG ZMT	ZOLMITRIPTAN ZMT	2.5 MG		20/34
ZYBAN	BUPROPION			168 tabs &/or 84 days/365
ZYPREXA (<13 YEARS OF AGE)	OLANZAPINE (<13 YEARS OF AGE)		15 MG	
ZYPREXA (>=13 YEARS OF AGE)	OLANZAPINE (>=13 YEARS OF AGE)		30 MG	